ClinicalTrials.gg
Not yet recruitingNCT05643131Updated Sep 17, 2025

Hyivy Device as Non-hormonal Therapy in Endometriosis

An interventional study of Hyivy Intravaginal Device in Endometriosis and Pelvic Pain, sponsored by Hyivy Health Inc. Not yet recruiting at 1 site in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-17.

Sponsored by Hyivy Health Inc · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Endometriosis with a site in Canada — 12 open to participants now, 13 under way, none of them phase 3. Endometriosis · Canada.

Planned enrollment
18th of 23
20 · median 64
Started
2025
with 2 others
No phase
11 of 34
6 open now
Primary completion
2026-12
later than 1 of 12 live
Registered
21st of 34
by date

Among the 34 studies in Endometriosis with a site in Canada, this one is the 18th largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2025, is one of 11 with no phase, reaches primary completion later than 1 of the 12 other live ones, and was the 21st registered.

Endometriosis

924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.

Browse Endometriosis studies →

Open to participants now

12 of the 34 studies in Endometriosis with a site in Canada are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Endometriosis with a site in Canada, or all of them as a file.
02

Study summary

This study seeks to address accessible management of endometriosis-associated chronic pelvic pain by evaluating a novel device used in the home. The study is designed as a proof-of-concept single-arm pilot study, and the primary objective is to assess change in overall self-reported pelvic pain in people with endometriosis-associated chronic pelvic pain following the use of the Hyivy intravaginal device.

Read the detailed description

Endometriosis is a chronic, inflammatory, estrogen-dependent disease characterized by ectopic growth of uterine-like cells outside the uterus. People living with endometriosis typically experience debilitating pelvic pain (dysmenorrhea, dyspareunia, dyschezia, dysuria, non-menstrual pelvic pain), and infertility. Endometriosis also has significant negative impacts on quality of life, physical, mental, and social wellbeing.

There is no diagnostic marker nor cure for this chronic disease. Current treatment options include medical therapies (mainly hormonal treatments aimed at suppressing menstruation or growth of the ectopic cells), surgery (to remove endometriotic lesions/nodules), and complementary or alternative therapies (non-medical or surgical options to manage symptoms; heat, mindfulness, diet, yoga, natural remedies, physical therapies, etc.).

Many people living with endometriosis report having used self-management strategies (complementary and alternative therapies) to manage their symptoms, and research on treatments and alternative therapies are consistently ranked among the top endometriosis research priorities. Alternative therapies have the potential to complement existing medical and surgical therapies, offering additional options to manage symptoms like pain.

03

Conditions studied

  • Endometriosis
  • Pelvic Pain

Keywords

  • Endometriosis
  • Pelvic Pain
  • Dilator
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Age ≥ 18 at the time of enrollment
  • 2.Generally in good health (other than due to endometriosis), at physician's discretion
  • 3.Diagnosed with endometriosis (clinical, radiologic, or surgical)
  • 4.Diagnosed with chronic pelvic pain (self-reported pain in pelvic area lasting >3 months)
  • 5.VAS for overall pelvic pain ≥ 4 at screening and baseline
  • 6.Medically managing endometriosis using continuous hormonal medications (i.e., oral pills, progesterone only pills, Mirena, GnRH agonists/antagonists) for at least 3 months prior to enrollment
  • 7.Agrees not to commence any new treatments (medical or physical therapies) for the 12-week intervention period, including hormonal therapies for any medical condition, and complimentary and/or alternative management of surgery for endometriosis and associated chronic pain
  • 8.Agrees not to undergo pelvic physiotherapy with a trained professional during the study
  • 9.Agrees to avoid taking non-steroidal anti-inflammatory drugs (e.g., ibuprofen) for 72 hours before Visits 1, 2, and 3
  • 10.Must have the ability to charge the device
  • 11.Must be willing and able to insert intravaginal device
  • 12.Able to understand, comply and consent to protocol requirements and instructions
  • 13.Able to attend scheduled study visits and complete required investigations

Exclusion criteria

Exclusion Criteria:

  • 1.Chronic pelvic pain thought to be due to a condition other than endometriosis
  • 2.Diagnosis of premature ovarian insufficiency
  • 3.Any other medical condition or clinical finding giving reasonable suspicion of a disease or condition that contraindicates the use of the product or that may affect the interpretation of the results or leave the patient at high risk from treatment complications, at the discretion of the investigator(s)
  • 4.Any surgery in the past 3 months or anticipates having surgery during the study
  • 5.Allergy to Hyivy device's materials
  • 6.Active vaginal infection (e.g. vulvovaginal candidiasis, trichomonas vaginitis, bacterial vaginosis, STIs) or infection in the pelvic area
  • 7.Current use of antibiotics and a history of vulvovaginal candidiasis
  • 8.Pregnant or lactating
  • 9.Currently under the care of a pelvic floor physiotherapist
  • 10.Have open wounds, cuts, or open sores present in vaginal or pelvic area
  • 11.Severe atrophic vaginitis or very dry, itchy, or sore vagina/vaginal area, at the discretion of the primary investigator(s)
  • 12.Hypoesthesia or loss in sensation of the pelvic floor
  • 13.Total and/or partial prolapse of the uterus and/or vagina
  • 14.Symptoms of severe urinary retention, severe extra-urethral incontinence or overflow incontinence
  • 15.Unable to position the device according to directions for use
  • 16.Use of any medical devices that may interfere with the investigational device's function, such as pacemakers, ventilators, and ear implants
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Hyivy Intravaginal Device

    Participants will receive a Hyivy intravaginal device for at-home use. Recommended use is three times per week for 12 weeks and consists of 10 minutes of heat (37-39ºC) and 10 minutes of dilation per session.

    Device: Hyivy Intravaginal Device

Interventions

  • DeviceHyivy Intravaginal Device

    Intravaginal use of Hyivy device three times per week for 12 weeks, with each session consisting of 10 minutes of heat (37-39ºC) and 10 minutes of dilation.

06

What researchers measure

Primary outcomes

  1. Overall self-reported pelvic pain

    Overall pelvic pain will be evaluated using a digital visual analog scale (VAS)

    Time frame: Baseline, 6-weeks, 12-weeks

Secondary outcomes

  1. Site-specific tenderness and pelvic floor muscle pain

    Site-specific tenderness and pelvic floor muscle pain will be measured by the Biberoglu and Behrman scale (B\&B) ranging from 0 (none) to 15 (severe) and patient exams

    Time frame: Baseline, 6-weeks, 12-weeks

  2. Quality of Life (EHP-30)

    Changes in quality of life as assessed by the Endometriosis Health Profile-30 (EHP-30) ranging from 0 (best possible health status) to 100 (worst possible health status).

    Time frame: Baseline, 6-weeks, 12-weeks

  3. Sexual Function (FSFI)

    Changes in sexual function as assessed by the Female Sexual Function Index (FSFI). Scores range from 2 to 36 with higher scores indicating greater functioning.

    Time frame: Baseline, 6-weeks, 12-weeks

  4. Safety and tolerability of the Hyivy device

    Occurrence of adverse events (AE) and serious adverse events (SAE).

    Time frame: Up to 12-weeks

  5. Adherence to study protocol

    Usage data collected by the Hyivy device will be used to assess participant adherence to the study regimen of 3 times/week device use.

    Time frame: 6-weeks, 12-weeks

  6. Feasibility of the Hyivy device

    Device usage will be assessed with a study-specific questionnaire.

    Time frame: 6-weeks, 12-weeks

  7. Use of rescue medication

    Changes in the use of rescue medications for chronic pelvic pain, assessed with a study-specific questionnaire.

    Time frame: Baseline, 6-weeks, 12-weeks

Other outcomes

  1. Autonomic function

    Autonomic nervous system (ANS) function will be assessed using measures of heart rate variability (HRV) during a deep breathing test, active standing test, and water intake test.

    Time frame: Baseline, 6-weeks, 12-weeks

  2. Peripheral gene expression

    Changes in peripheral inflammation as assessed by a protein biomarker panel before and after device use

    Time frame: Baseline, 6-weeks, 12-weeks

  3. Emergency room (ER) visits

    Number of ER visits due to chronic pelvic pain in the last 6 weeks

    Time frame: Baseline, 6-weeks, 12-weeks

  4. Device usability and patient satisfaction

    Study-specific questionnaire to gather patient feedback

    Time frame: 12-weeks

07

Study locations

1 site
08

References and documents

Publications

  • Singh S, Soliman AM, Rahal Y, Robert C, Defoy I, Nisbet P, Leyland N. Prevalence, Symptomatic Burden, and Diagnosis of Endometriosis in Canada: Cross-Sectional Survey of 30 000 Women. J Obstet Gynaecol Can. 2020 Jul;42(7):829-838. doi: 10.1016/j.jogc.2019.10.038. Epub 2020 Jan 27. PubMed 32001176 ↗
  • Kong S, Zhang YH, Liu CF, Tsui I, Guo Y, Ai BB, Han FJ. The complementary and alternative medicine for endometriosis: a review of utilization and mechanism. Evid Based Complement Alternat Med. 2014;2014:146383. doi: 10.1155/2014/146383. Epub 2014 Feb 19. PubMed 24701237 ↗
  • Vercellini P, Vigano P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014 May;10(5):261-75. doi: 10.1038/nrendo.2013.255. Epub 2013 Dec 24. PubMed 24366116 ↗
  • Becker CM, Gattrell WT, Gude K, Singh SS. Reevaluating response and failure of medical treatment of endometriosis: a systematic review. Fertil Steril. 2017 Jul;108(1):125-136. doi: 10.1016/j.fertnstert.2017.05.004. PubMed 28668150 ↗
  • As-Sanie S, Black R, Giudice LC, Gray Valbrun T, Gupta J, Jones B, Laufer MR, Milspaw AT, Missmer SA, Norman A, Taylor RN, Wallace K, Williams Z, Yong PJ, Nebel RA. Assessing research gaps and unmet needs in endometriosis. Am J Obstet Gynecol. 2019 Aug;221(2):86-94. doi: 10.1016/j.ajog.2019.02.033. Epub 2019 Feb 18. PubMed 30790565 ↗
  • Duffy J, Hirsch M, Vercoe M, Abbott J, Barker C, Collura B, Drake R, Evers J, Hickey M, Horne AW, Hull ML, Kolekar S, Lensen S, Johnson NP, Mahajan V, Mol BW, Otter AS, Puscasiu L, Rodriguez MB, Rombauts L, Vail A, Wang R, Farquhar CM; endo:outcomes - an International Collaboration Harmonising Outcomes and Outcome Measures for Endometriosis Research. A core outcome set for future endometriosis research: an international consensus development study. BJOG. 2020 Jul;127(8):967-974. doi: 10.1111/1471-0528.16157. Epub 2020 Mar 30. PubMed 32227676 ↗
  • Nnoaham KE, Hummelshoj L, Webster P, d'Hooghe T, de Cicco Nardone F, de Cicco Nardone C, Jenkinson C, Kennedy SH, Zondervan KT; World Endometriosis Research Foundation Global Study of Women's Health consortium. Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries. Fertil Steril. 2011 Aug;96(2):366-373.e8. doi: 10.1016/j.fertnstert.2011.05.090. Epub 2011 Jun 30. PubMed 21718982 ↗

Individual participant data

Plan to share: No — There is no plan to make individual participant data available to other researchers.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2025; primary completion for Dec 2026, 14 months later.

Of 214 interventional studies with no phase under Endometriosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 44. This study's planned 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2022
First posted
Dec 8, 2022
StartEst.
Oct 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Sep 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05643131
Lead sponsor
Hyivy Health Inc
Collaborators
McMaster University
Responsible party
Sponsor
First posted
Dec 8, 2022
Start date
Oct 2025 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 17, 2025

Study contacts

Mathew Leonardi, M.D.
Contact
leonam@mcmaster.ca
905-521-2100 ext. 76252
Mathew Leonardi, M.D.
principal investigator · McMaster University Medical Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion